Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model

• Published in: Turkish journal of urology 2017-12, Vol.43 (4), p.434-438
• Main Authors: Caliskan, Selahattin, Keles, Muzaffer Oguz, Ozturk, Metin Ishak, Kutluhan, Musab Ali, Tok, Olgu Enis, Ercan, Feriha, Karaman, Muhammet Ihsan
• Format: Article
• Language: English
• Subjects: Andrology; Genital diseases; Hyperplasia; Prostate; Rodents; Urology
• ISSN: 2149-3235; 2149-3057; 2980-1478
• DOI: 10.5152/tud.2017.23356

Objective: Efficacy of treatments for benign prostate hyperplasia (BPH) is limited because the disease has complex etiopathogenesis. Recent studies have demonstrated the presence of phosphodiesterase-5 (PDE-5) receptors in prostate tissue. We investigated efficacy of sildenafil citrate in testosteron - induced BPH in rats. Material and methods: The rats were divided into three groups. Each groups had 7 rats. Group 1 was control group. Testosteron propionate 3 mg/kg/day was injected subcutaneously for two weeks in Group 2. The same procedure was done for Group 3 and sildenafil citrate was added to water at daily doses of 2 mg/kg for two weeks. The rats were euthanized with intraperitoneal pentobarbital. The body weights were measured and the prostates were removed. Results: The mean weights of rats were 288±31.93, 345±23.23 and 294±32.86 g in Groups 1, 2 and 3, respectively. The mean prostate weights of rats were 0.74±0.18, 1.3±0.13 and 0.72±0.24 g in Groups 1, 2, and 3, respectively. Group 2 had statistically significantly higher prostate weights than the other groups (p